Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence.
Lee C, Check DK, Manace Brenman L, Kushi LH, Epstein MM, Neslund-Dudas C, Pawloski PA, Achacoso N, Laurent C, Fehrenbacher L, Habel LA. Lee C, et al. Among authors: fehrenbacher l. Breast Cancer Res Treat. 2020 Feb;180(1):219-226. doi: 10.1007/s10549-020-05539-z. Epub 2020 Jan 23. Breast Cancer Res Treat. 2020. PMID: 31975315 Free PMC article.
Use of raloxifene among women with a history of breast cancer.
Habel LA, Pressman A, Ettinger B, Sidney S, Suh-Burgmann B, Fehrenbacher L, Quesenberry CP. Habel LA, et al. Among authors: fehrenbacher l. Breast Cancer Res Treat. 2006 Mar;96(2):123-9. doi: 10.1007/s10549-005-9069-8. Breast Cancer Res Treat. 2006. PMID: 16319985
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.
Habel LA, Shak S, Jacobs MK, Capra A, Alexander C, Pho M, Baker J, Walker M, Watson D, Hackett J, Blick NT, Greenberg D, Fehrenbacher L, Langholz B, Quesenberry CP. Habel LA, et al. Among authors: fehrenbacher l. Breast Cancer Res. 2006;8(3):R25. doi: 10.1186/bcr1412. Epub 2006 May 31. Breast Cancer Res. 2006. PMID: 16737553 Free PMC article.
Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system.
Fehrenbacher L, Capra AM, Quesenberry CP Jr, Fulton R, Shiraz P, Habel LA. Fehrenbacher L, et al. J Clin Oncol. 2014 Jul 10;32(20):2151-8. doi: 10.1200/JCO.2013.52.0858. Epub 2014 Jun 2. J Clin Oncol. 2014. PMID: 24888815
Reply to L. Cabel et al.
Fehrenbacher L, Capra A, Habel L. Fehrenbacher L, et al. J Clin Oncol. 2015 Jan 20;33(3):292-3. doi: 10.1200/JCO.2014.58.9671. Epub 2014 Dec 15. J Clin Oncol. 2015. PMID: 25512452 No abstract available.
Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study.
Tan AR, Johannes H, Rastogi P, Jacobs SA, Robidoux A, Flynn PJ, Thirlwell MP, Fehrenbacher L, Stella PJ, Goel R, Julian TB, Provencher L, Bury MJ, Bhatt K, Geyer CE Jr, Swain SM, Mamounas EP, Wolmark N. Tan AR, et al. Among authors: fehrenbacher l. Breast Cancer Res Treat. 2015 Jan;149(1):163-9. doi: 10.1007/s10549-014-3221-2. Epub 2014 Dec 27. Breast Cancer Res Treat. 2015. PMID: 25542269 Clinical Trial.
136 results